Figure 1.
Figure 2.
ATC classification of gonadorelina registered forms which is used for treatment od advent tumors prostate in Republic of Serbia
| Mark | Clasification | DDD (1000/day)23 | Method of administration/application |
|---|---|---|---|
| L | Antineoplastic and immunomodulators | ||
| 02 | Endocrinological therapy | ||
| A | Hormones and related drugs | ||
| E | Gonadorelin-releasing hormone analogues | ||
| 02 | Leuprorelin16,17 | 60 mcg | intramuscular / subcutaneous |
| 03 | Goserelin18,19 | 0,129 mg | subcutaneous |
| 04 | Triptorelin20,21,22 | 0,134 mg | intramuscular (i.m.) |
Comparative data on the consumption of gonadorelin analogues at the Clinic of Urology of the University Medical Center Kragujevac, as well as in Serbia, Croatia and Italy by years_
| International Nonproprietary Name/region | Consumption of LHRH agonists in DDD / 1000 / day ** per year | ||||
|---|---|---|---|---|---|
| 2016 | 2017 | 2018 | 2019 | 2020 | |
| Clinic of Urology, UCC Kragujevac | |||||
| Leuprorelin | 0,0020 | 0,0022 | 0,0005 | 0,0017 | 0,0184 |
| Goserelin | 0,0028 | 0,0037 | 0,0054 | 0,0070 | 0,0035 |
| Triptorelin | 0,0353 | 0,0316 | 0,0441 | 0,0489 | 0,0394 |
| Total | 0,0402 | 0,0375 | 0,0500 | 0,0576 | 0,0613 |
| Serbia12 | |||||
| Leuprorelin | 0,0563 | 0,0720 | 0,0014 | 0,0055 | N/A * |
| Goserelin | 0,1035 | 0,0841 | 0,0832 | 0,0821 | N/A |
| Triptorelin | 0,1927 | 0,2076 | 0,2706 | 0,2817 | N/A |
| Total | 0,3526 | 0,3637 | 0,3552 | 0,3694 | N/A |
| Croatia13 | |||||
| Leuprorelin | 0,5700 | 0,5800 | 0,5900 | 0,7800 | N/A |
| Goserelin | 0,0900 | 0,1100 | 0,1300 | 0,1900 | N/A |
| Triptorelin | 0,0300 | 0,0300 | 0,2300 | 0,2300 | N/A |
| Total | 0,6900 | 0,7200 | 0,9500 | 1,2000 | N/A |
| Italy14 | |||||
| Leuprorelin | N/A | 0,2000 | 0,2000 | 0,2000 | N/A |
| Goserelin | N/A | 0,0000 | 0,0000 | 0,0000 | N/A |
| Triptorelin | N/A | 0,7000 | 0,8000 | 0,8000 | N/A |
| Total | N/A | 0,9000 | 1,0000 | 1,0000 | N/A |
Overview of the five-year consumption of all LHRH agonists used, depending on the dose and formulation of the drug
| International Nonproprietary Name – INN formulation | Proprietary name | Dosage | Pharmaceutical formulation | Consumption (DDD/1000/day) |
|---|---|---|---|---|
| leuprorelin (monthly) | Lupron® 3.75 mg/ml | 3.75 mg/ml | Powder and solvent for suspension for injection in a pre-filled syringe | 0,004357974 |
| leuprorelin (q3-month) | Lupron® 11.25 mg/ml | 11.25 mg/ml | Powder and solvent for suspension for injection in a pre-filled syringe | 0,001289482 |
| leuprorelin (q3-month) | Lutrate depo® 22.5mg | 22.5 mg | Powder and solvent for prolonged-release suspension for injection | 0,019165 |
| goserelin (monthly) | Zoladex® | 3.6 mg | Implant, in pre-filled syringe | 0,019552701 |
| goserelin (q3-month) | Zoladex® LA | 10.8 mg | Implant, in pre-filled syringe | 0,002876386 |
| triptorelin (monthly) | Diphereline® 3.75 mg/2 ml | 3.75 mg/2 ml | Powder and solvent for prolonged-release suspension for injection | 0,176707295 |
| triptorelin (q3-month) | Diphereline® 11.25 mg/2 ml | 11.25 mg/2 ml | Powder and solvent for prolonged-release suspension for injection | 0,021587071 |
| triptorelin (q6-month) | Diphereline® 22.5 mg/2 mL | 22.5 mg/2 ml | Powder and solvent for prolonged-release suspension for injection | 0,00096538 |